[Concurrent chemotherapy and hyperfractionated radiotherapy for non-operable carcinoma of the bladder].
Two sequences of concomitant chemotherapy with 5-FU + cisplatin and hyperfractionated radiotherapy (67.2 Gy/56 fractions/38 days, two fractions of 1.2 Gy per day spaced to 6 hours) in the bladder volume were administered to 17 patients with infiltrative carcinoma of the bladder (1 pT1, 6 pT2, 8 pT3a, 2 pT3b or pT4, 8/17 N0-2). They were separated by an interval of 21 days with an intermediate bladder tumor evaluation. A complete histological response was observed in 69% (11 of 16 evaluable patients). With a mean follow-up of 21 months, the bladder preservation was stated in 8/11 (73%) of patients treated, of whom 6 with a complete tumor response, and 2 with a pTa recurrence; these results are similar to other series reported with conventional radiation therapy. No deficit in the bladder was observed in these eight patients.
Schmitt
T
T
Service de radiothérapie, CHU de Saint-Etienne, France.
Armand
C
C
Mille
D
D
Favrel-Tchakamian
V
V
Gilloz
A
A
D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*
D002945:Cisplatin; D005472:Fluorouracil